Retired tech leader makes $16.25M donation to Houston health care organization

a meaningful gift

Howard and Susan Elias donated $16.25 million to the University of Texas MD Anderson Cancer Center. Photo via mdanderson.org

Earlier this year, an executive at Dell Technologies announced his retirement and commitment to philanthropy. Just a few months later, he and his wife made a whopping donation to the Houston health care organization that's responsible for curing their son.

Howard and Susan Elias donated $16.25 million to the University of Texas MD Anderson Cancer Center, the organization announced this week. The gift will go toward accelerating brain tumor and cancer neuroscience research. Howard Elias, who held C-level roles at EMC Corp. and Dell Technologies after EMC's acquisition in 2015, retired in April.

The Eliases have supported MD Anderson since Harrison, Howard and Susan's son, was diagnosed with brain cancer. In 2000, Harrison underwent a successful surgery by Dr. Frederick Lang.

“Dr. Lang and the incredible team at MD Anderson saved my son’s life more than two decades ago,” says Howard in a news release. “Now is the time for us to increase our commitment so we can play a significant role in advancing cancer neuroscience research specifically focused on brain tumors and the nervous system. We want other families to have the chance to see their son grow up, like our family has.”

The donation is the lead donation to concentrate cross-disciplinary research in cancer neuroscience, per the release.

“Our focus is on unraveling the fundamental scientific principles driving the cancer-neuroscience interaction,” Lang says in the release. “These advances will drive prevention, early detection and possibly even cures for neurological cancers; will lead to strategies to overcome the adverse effects of cancer treatments on the nervous system; and will address mental health needs in cancer patients, with the ultimate result of dramatically improving outcomes.”

Lang leads the Cancer Neuroscience Program alongside Dr. Vinay Puduvalli, M.D., chair of Neuro-oncology;and Jim Ray, Ph.D., director of the Neurodegeneration Consortium.

“A future free from cancer is unattainable unless we work together,” says Dr. Peter WT Pisters, president of MD Anderson. “Howard and Susan’s generosity and passion will play a crucial role as we work in this emerging space for generations to come. On behalf of our patients and their families, we extend our heartfelt gratitude.”

From Your Site Articles
Five cancer research teams have been selected to receive funds from a new initiative from the University of Texas. Photo via news.utexas.edu

UT system funds Houston researchers in new collaboration to cure cancer

collaborate for a cure

In a renewed effort to move the needle on finding a cure for cancer, the University of Texas system has launched a new collaboration in oncological data and computational science across three programs.

Houston-based University of Texas MD Anderson Cancer Center has teamed up with two UT Austin schools — the Oden Institute for Computational Engineering and Sciences and the Texas Advanced Computing Center. The collaboration was announced this summer to tap into mathematical modeling and advanced computing along with oncology expertise to inspire new methods of cancer treatment.

"Integrating and learning from the massive amount of largely unstructured data in cancer care and research is a formidable challenge," says David Jaffray, Ph.D., chief technology and digital officer at MD Anderson, in a news release. "We need to bring together teams that can place quantitative data in context and inform state-of-the-art computational models of the disease and accelerate progress in our mission to end cancer."

Now, the first five projects to be funded under this new initiative have been announced.

  • Angela Jarrett of the Oden Institute and Maia Rauch of MD Anderson will develop a patient-specific mathematical model for forecasting treatment response and designing optimal therapy strategies for patients with triple-negative breast cancer.
  • Caroline Chung of MD Anderson and David Hormuth of the Oden Institute are using computational models of the underlying biology to fundamentally change how radiotherapy and chemotherapy are personalized to improve survival rates for brain cancer patients.
  • Ken-Pin Hwang of MD Anderson and Jon Tamir of UT Austin's Department of Electrical and Computer Engineering and the Oden Institute will use mathematical modeling and massively parallel distributed computing to make prostate MR imaging faster and more accurate to reduce the incidence of unnecessary or inaccurate biopsies.
  • Xiaodong Zhang of MD Anderson and Hang Liu of TACC will advance both the planning and delivery of proton therapy via a platform that combines mathematical algorithms and high-performance computing to further personalize these already highly tailored treatments.
  • Tinsley Oden and Prashant Jha of the Oden Institute and David Fuentes of MD Anderson will integrate a new mechanistic model of tumor growth with an advanced form of MRI to reveal underlying metabolic alterations in tumors and lead to new treatments for patients.

"These five research teams, made up of a cross section of expertise from all three stakeholders, represent the beginning of something truly special," says Jaffray in a release. "Our experts are advancing cancer research and care, and we are committed to working with our colleagues at the Oden Institute and TACC to bring together their computational expertise with our data and insights."

Later this month, the five teams will log on to a virtual retreat along with academic and government thought leaders to further collaborate and intertwine their research and expertise.

"Texas is globally recognized for its excellence in computing and in cancer research. This collaboration forges a new path to international leadership through the combination of its strengths in both," says Karen Willcox, director of the Oden Institute. "We are thrilled that leaders in government, industry and academia see the potential of this unique Texan partnership. We're looking forward to a virtual retreat on October 29 to continue to build upon this realization."

Houston Methodist stood out yet again on an annual best hospitals report, but several other Houston institutions were recognized as well. Courtesy of Methodist Hospital/Facebook

New report recognizes best hospitals in Houston

better than all the rest

Hospitals across Houston were ranked by their patient care, patient safety, outcomes, nursing, advanced technology and reputation in an annual report that identifies the top medical facilities in the country.

U.S. News & World Report released its 31st annual best hospital rankings this week, which included both adult and children's hospital tracks across several categories. The report released both overall and local rankings after evaluating over 4,500 medical centers nationwide in 16 specialties, and 134 hospitals were ranked in at least one specialty.

For the ninth year in a row, the top hospital in Houston and Texas, according to the report, is Houston Methodist, which ranked at No. 20 nationally and made the report's Honor Roll.

"Our U.S. News rankings are especially meaningful right now as this has been an exceptionally difficult time for our health care workers," says Marc Boom, M.D., president and CEO of Houston Methodist, in a news release. "We have always served our community by providing exceptional care — during the COVID-19 pandemic and before. It's a true testament to our commitment to being unparalleled."

Houston Methodist Sugar Land Hospital tied for No. 4 in Houston and No. 6 (three-way tie) in Texas. Additionally, the hospital was recognized on the top lists for 11 specialties:

  • No. 12 for cardiology/heart surgery
  • No. 13 for orthopedics
  • No. 14 for gastroenterology/GI surgery
  • No. 17 for cancer
  • No. 19 (tie) for nephrology
  • No. 20 for pulmonology and lung surgery
  • No. 23 for neurology/neurosurgery
  • No. 26 for geriatrics
  • No. 26 (tie) for gynecology
  • No. 28 for diabetes and endocrinology
  • No. 49 for ear, nose and throat

The second-best hospital in Houston on this year's ranking was Baylor St. Luke's Medical Center, which was also named the No. 3 hospital in the state.

"At Baylor St. Luke's, we are transforming the way we deliver care for our patients through groundbreaking technologies and a multidisciplinary approach that allows us to give the best possible care to patients and their families," says Doug Lawson, CEO of St. Luke's Health, in a news release. "I praise our dedicated staff and physicians for helping us achieve this recognition."

Baylor St. Luke's also made an appearance across five specialties:

  • No. 17 for cardiology/heart surgery
  • No. 21 for gastroenterology/GI surgery
  • No. 21 for neurology/neurosurgery
  • No. 27 for cancer
  • No. 47 for geriatrics

"This is a great report that confirms the efforts of our partnership at Baylor St. Luke's and our affiliated hospitals to provide unsurpassed care to patients, conduct research that will change lives and train the next generation of physicians", says Dr. Paul Klotman, president, CEO, and executive dean at Baylor College of Medicine. "Baylor St. Luke's high ranking in Texas is in parallel with Baylor College of Medicine being the highest ranked medical school in Texas. Together, we are an outstanding academic medical center and learning health system."

Memorial Hermann - Texas Medical Center came in No. 3 in Houston and No. 5 in Texas. The hospital ranked in one adult specialty and two children's specialties.

  • No. 43 for ear, nose and throat (adult)
  • No. 22 for cardiology/heart surgery (pediatric)
  • No. 31 for neurology/neurosurgery (pediatric)

On the children's hospital track, Houston's Texas Children's Hospital ranked as No. 4 nationally and was recognized in all 10 pediatric specialties, which included:

  • No. 1 for pediatric cardiology/heart surgery
  • No. 2 for pediatric nephrology
  • No. 2 for pediatric neurology/neurosurgery
  • No. 3 for pediatric pulmonology and lung surgery
  • No. 4 for pediatric cancer
  • No. 5 for pediatric diabetes and endocrinology
  • No. 5 for pediatric gastroenterology/GI surgery
  • No. 6 for pediatric urology
  • No. 10 for neonatology
  • No. 15 for pediatric orthopedics

Zooming in on the specific specialties, several other Houston hospitals in addition to these top tier hospitals, secured spots in the top 10 rankings.

University of Texas MD Anderson Cancer Center was ranked No. 1 nationally for adult cancer treatment. Additionally, the hospital made an appearance in six other adult specialties and one pediatric specialty.

  • No. 4 for ear, nose and throat
  • No. 6 for urology
  • No. 14 for gynecology
  • No. 27 for diabetes and endocrinology
  • No. 41 for geriatrics
  • No. 46 for gastroenterology/GI surgery
  • No. 38 for cancer (pediatric)
TIRR Memorial Hermann in Houston ranked No. 3 nationally for rehabilitation.
For all 31 years, The Menninger Clinic has been recognized as a top hospital in the psychiatric speciality. This year, the clinic ranked at No. 9 nationally.

"Our clinical teams provide personalized care with the right blend of art and science. We have pioneered measuring the effectiveness of this treatment, and the results consistently demonstrate that patients sustain their well-being for at least a year after they leave Menninger," says Armando Colombo, president and CEO, in a news release. "Going forward, we will improve access to make it easier for more Texans to access these life-changing results."

Othram and the University of Texas M.D. Anderson Cancer Center have teamed up to create a modern forensic sequencing lab program. Getty Images

New program in Houston is training future forensic scientists and digitizing DNA evidence

crime scene innovation

Houston-area's first-privately held forensic sequencing laboratory has partnered with The University of Texas M.D. Anderson Cancer Center to create an academic program that will provide forensic training to genome scientists that will help them crack previously unsolved criminal cases.

Othram was created in 2018 specifically to apply the power of modern DNA parallel sequences to forensic evidence. Its new academic program partnership is aimed at training Molecular Genetic Technology (MGT) graduate students in the newest laboratory techniques and technology for the recovery and analysis of human DNA from deteriorated or contaminated materials.

"Because this field is so new, there aren't many individuals who are experts in both genomics and forensic science," David Mittelman, CEO and founder of Othram, tells InnovationMap. "We wanted to collaborate with M.D. Anderson who has a great genetic testing program already to help students learn about how to apply current techniques that are being used to solve cases that no one else can solve."

MGT students, who study the role of genetics in medicine, will be able to train with Othram experts using new technological advances such as the ability to harness whole-genome shotgun sequencing for the unique needs that forensic evidence demands like human identification.

"The Texas Medical Center is the best in the world, specifically for genomics training so it seemed like a natural fit," says Mittelman. "Especially since we want to attract and expose students to this new area of forensics as a possible outlet."

The use of new technology is what sets Othram apart, last year they helped solved a 103-year old mystery of a headless torso found in an Idaho cave, using their Forensic-Grade Genome SequencingTM technology. The DNA extraction and sequencing lab at Othram distill the sample DNA down to a sequence, which with the help of computer software, can be analyzed to reconstruct the whole genome of an individual's DNA.

Then the DNA is digitized and matched to other databases such as the FBI's Combined DNA Index System to cross-reference for a DNA match. With Othram's ability to construct whole genomes from previously unusable DNA samples, they can further the search to identify human remains or identify suspects from living relatives.

"There is no one currently leveraging whole genome sequencing right now like Othram," says Mittelman. "There's a whole range of opportunities from taking a look at the whole genome from ancestry to relationship testing and physical trait prediction."

The unique learning experience for MGT students will integrate classroom lectures, laboratory demonstrations, and technological experiences. Mittleman says that the academic program partnership will enable a new generation of forensic genomics scientists to digitize the nation's DNA evidence and solve cold cases.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings